-
Cryofocus Medtech Partners with Guangzhou Medical University Hospital for Cryoballoon Ablation R&D
•
Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the First Affiliated Hospital of Guangzhou Medical University have entered into a collaborative agreement to contribute to the Guangzhou Lab’s project establishment and management. Guangzhou Lab is a cutting-edge research institution dedicated to the prevention and…
-
Cryofocus Medtech Partners with Boston Scientific for Respiratory Products Distribution in China
•
Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced a strategic distribution agreement with the Shanghai subsidiary of US medical device giant Boston Scientific Corporation (NYSE: BSX). As per the terms of the agreement, Cryofocus is set to become the exclusive marketing partner and…
-
Cryofocus Medtech Secures NMPA Approval for Cryotherapy Equipmen
•
Shanghai-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its cryotherapy equipment, which supports its innovative frozen adhesion treatment system. The cryotherapy equipment comprises a main unit, a foot switch, and an exhaust pipe, and…
-
Cryofocus Medtech Receives NMPA Approval for Complete Cardiac Cryoablation System
•
Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced that it has received marketing approvals from China’s National Medical Products Administration (NMPA) for all components of its cardiac cryoablation system. The approvals include the cryoablation equipment, balloon type cryoablation catheter (previously known as the…
-
Cryofocus Medtech Set for IPO on Hong Kong Stock Exchange
•
China-based Cryofocus Medtech (Shanghai) Co., Ltd, a minimally invasive interventional cryotherapy device maker, is set to make an initial public offering (IPO) of 11.11 million shares to the Hong Kong Stock Exchange, priced at HKD 18.9 (USD 2.43) per share. This amounts to an HKD 210 million (USD 27 million)…
-
Cryofocus Biotechnology’s RDN System Gains FDA Breakthrough Therapy Designation
•
Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd’s in-house developed Cryofocus RDN System, a cryoablation renal denervation product, has obtained breakthrough therapy designation (BTD) status from the US FDA for use in refractory hypertension. Regulatory Milestones and InnovationsThe Cryofocus RDN System, the first of its kind globally, previously passed…
